Surveillance of patients after initial treatment of ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 1, 2009, Pages 43-52

  Gadducci, Angiolo ^a   Cosio, Stefania ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

CA 125; Computed tomography; Follow up; Magnetic resonance imaging; Ovarian cancer; Physical examination; Positron emission tomography; Positron emission tomography computed tomography; Secondary cytoreductive surgery; Ultrasound

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DIAPHRAGM DISEASE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY;

CA-125 ANTIGEN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67349204858     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.12.008     Document Type: Review

References (121)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Morris C.R., Rodriguez A.O., Epstein J., and Cress R.D. Declining trends of epithelial ovarian cancer in California. Gynecol Oncol 108 (2008) 207-213
3. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., and Randall M.E. (Eds). Principles and practices of gynecologic oncology. 4th ed. (2005), Lippincott Williams & Wilkins, Philadelphia 895-977
4. Heintz A.P.M., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. Int J Gynecol Obstet 95 Suppl. 1 (2006) S161-S192
5. Trimbos J.B., Parmar M., Vergote I., et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst 95 (2003) 105-112
6. Fader A.N., and Rose P.G. Role of surgery in ovarian carcinoma. J Clin Oncol 25 (2007) 2873-2883
7. Leitao Jr. M.M., and Chi D.S. Operative management of primary epithelial ovarian cancer. Curr Oncol Rep 9 (2007) 478-484
8. Tropé C., and Kaern J. Adjuvant chemotherapy for early stage ovarian cancer: review of the literature. J Clin Oncol 25 (2007) 2909-2920
9. Bell J., Brady M.F., Young R.C., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102 (2006) 432-439
10. Markman M. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 105 (2007) 279-280
11. Vergote I.B., Vergote-De Vos L.N., Abeler V.M., et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69 (1992) 741-749
12. Rubin S.C., Wong G.Y., Curtin J.P., Barakat R.R., Hakes T.B., and Hoskins W.J. Platinum-based chemotherapy of high-risk stage I ovarian cancer following comprehensive surgical staging. Obstet Gynecol 82 (1993) 143-147
13. Malmstrom H., Simonsen E., and Westberg R. A Phase II study of intraperitoneal carboplatin as adjuvant treatment in early stage ovarian cancer patients. Gynecol Oncol 52 (1994) 20-25
14. Bolis G., Colombo N., Pecorelli S., et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 6 (1995) 887-893
15. Gadducci A., Sartori E., Maggino T., et al. Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study. Int J Gynecol Cancer 7 (1997) 445-450
16. Ozols R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33 2 Suppl 6 (2006) S3-S11
17. Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2007;(4):CD005343.
18. Neijt J.P., Engelholm S.A., Tuxen M.K., et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18 (2000) 3084-3092
19. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
20. Bristow R.E., and Montz F.J. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83 (2001) 39-48
21. Eisenkop S.M., Spirtos N.M., and Lin W.C. Optimal cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103 (2006) 329-335
22. Pomel C., Jeyarajah A., Oram D., et al. Cytoreductive surgery in ovarian cancer. Cancer Imaging 7 (2007) 210-215
23. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Aghajanian C., Barakat R.R., and Chi D.S. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108 (2008) 276-281
24. Gadducci A., Sartori E., Maggino T., et al. Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 68 (1998) 150-155
25. Thigpen JT. Current controversies in ovarian cancer: maintenance chemotherapy as standard care. In: Perry MC (Ed.). American society of clinical oncology, 2004 educational book. 40th Annual Meeting, June 5-8, 2004. New Orleans, LA, Spring 2004, Alexandria, VA, p. 281-284.
26. Gadducci A., Cosio S., Conte P.F., and Genazzani A.R. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55 (2005) 153-166
27. Markman M., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21 (2003) 2460-2465
28. Conte PF, Favalli G, Gadducci A, et al. Final results of After-6 protocol 1: a phase III trial of observation vs. 6 courses of paclitaxel (Pac) in advanced ovarian cancer patients in complete response (CR) after platinum-paclitaxel chemotherapy (CT). J Clin Oncol. 2007, ASCO Annual Meeting Proc Part I 2007;25 (20 Suppl.):5505.
29. Ovarian cancer: screening, treatment, and follow-up. NIH Consensus Statement. 1994;12:1-30.
30. Vaidya A.P., and Curtin J.P. The follow-up of ovarian cancer. Semin Oncol 30 (2003) 401-412
31. von Georgi R., Schubert K., Grant P., and Munstedt K. Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 114 (2004) 228-233
32. Gadducci A., Cosio S., Zola P., Landoni F., Maggino T., and Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 17 (2007) 21-31
33. van der Burg M.E., Lammes F.B., and Verweij J. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 176 (1993) 310-314
34. Rustin G.J.S., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
35. Bast Jr. R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., and Mills G.B. CA 125: the past and the future. Int J Biol Markers 13 (1998) 179-187
36. Gadducci A., Cosio S., Carpi A., Niccolini A., and Genazzani A.R. Serum tumor markers in the managment of ovarian, endometrial and cervical cancer. Biomed Pharmacother 58 (2004) 24-38
37. Gadducci A., Landoni F., Maggino T., et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer 7 (1997) 78-83
38. Rustin G.J., Timmers P., Nelstrop A., et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24 (2006) 45-51
39. Vergote I., Rustin G.J.S., Eisenhauer E.A., Mahmoudi M., and Meyert T. New guidelines to evaluate the response to treatment in solid tumours (ovarian cancer). J Natl Cancer Inst 92 (2000) 1534-1535
40. Rustin G.J., Marples M., Nelstrop A.E., Mahmoudi M., and Meyer T. Use of CA 125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19 (2001) 4054-4057
41. Tuxen M.K., Soletormos G., Rustin G.J., Nelstrop A.E., and Dombernowsky P. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scand J Clin Lab Invest 60 (2000) 713-721
42. Wilder J.L., Pavlik E., Straughn J.M., et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 89 (2003) 233-235
43. Santillan A., Garg R., Zahurak M.L., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23 (2005) 9338-9343
44. Menczer J. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 96 (2005) 906-907
45. Fleming L.W. Playing the waiting game: the asymptomatic patient with recurrent ovarian cancer detected only by rising Ca125 levels. Scott Med J 46 (2001) 81-83
46. Armstrong D.K. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 7 Suppl 5 (2002) 20-28
47. Hacker N.F., and Friedlander M. Treatment of recurrent ovarian cancer. Chang Gung Med J 27 (2004) 570-577
48. Medical Research Council Clinical Trial Unit. http://www.ctu.mrc.ac.uk/studies/OV05.asp.
49. Kainz C., Prayer L., Gitsch G., et al. The diagnostic value of magnetic resonance imaging for the detection of tumor recurrence in patients with carcinoma of the ovaries. J Am Coll Surg 178 (1994) 239-244
50. Sugiyama T., Nishida T., Komai K., Nishimura H., Yakushiji M., and Nishimura H. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynaecol Obstet 54 (1996) 251-256
51. Testa A.C., Ciampelli M., Mastromarino C., et al. Detection of central pelvic recurrent disease with transvaginal color doppler ultrasound in women treated for gynecological malignancy. Ultrasound Obstet Gynecol 19 (2002) 490-495
52. Wu X.F., Chen H.Z., and Han D.F. Diagnosis and treatment of recurrent epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 38 (2003) 664-666
53. Caserta D., Marci R., Porzio G., Di Roma E., and Moscarini M. Pelvic relapses in ovarian cancer: role of CA-125, transvaginal ultrasound and color Doppler. Eur J Gynaecol Oncol 24 (2003) 269-270
54. Fehm T., Heller F., Kramer S., Jager W., and Gebauer G. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res 25 (2005) 1551-1554
55. Grabiec M., Walentowicz M., and Nowicki P. The value of FDG PET/CT, ultrasound and CT in diagnosing recurrent ovarian carcinoma. Ginekol Pol 77 (2006) 746-752
56. Zeng H., Pei X.Q., Zheng D.M., Zhao Y.L., and Chen X.Y. Transvaginal color doppler ultrasonography and CA125 detection in surveillance of ovarian malignant tumors after operation. Ai Zheng 25 (2006) 1296-1299
57. Vuento M., Salmi T., Klemi P., and Grénman S. Ultrasonographic-guided pervaginal cul-de-sac cytology in the follow-up of ovarian carcinoma. Anticancer Res 27 (2007) 1015-1018
58. Prayer L., Kainz C., Kramer J., et al. CT and MR accuracy in the detection of tumor recurrence in patients treated for ovarian cancer. J Comput Assist Tomogr 17 (1993) 626-632
59. Ferrozzi F., Bova D., De Chiara F., et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging 22 (1998) 364-370
60. Kubik-Huch R.A., Dorffler W., von Schulthess G.K., et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 10 (2000) 761-767
61. Garcia Velloso M.J., Boan Garcia J.F., Villar Luque L.M., Aramendia Beitia J.M., Lopez Garcia G., and Richter Echeverria J.A. F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence: comparison with CT scan and CA 125. Rev Esp Med Nucl 22 (2003) 217-223
62. Soussan M., Wartski M., Cherel P., et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol 108 (2008) 160-165
63. Sebastian S., Lee S.I., Horowitz N.S., et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom Imaging 33 (2008) 112-118
64. Buy J.N., Moss A.A., Ghossain M.A., et al. Peritoneal implants from ovarian tumors: CT findings. Radiology 169 (1988) 691-694
65. Halvorsen Jr. R.A., Panushka C., Oakley G.J., Letourneau J.G., and Adcock L.L. Intraperitoneal contrast material improves the CT detection of peritoneal metastases. AJR 157 (1991) 37-40
66. Jacquet P., Jelinek J.S., Steves M.A., and Sugarbaker P.H. Evaluation of computed tomography in patients with peritoneal carcinomatosis. Cancer 72 (1993) 1631-1636
67. Coakley F.V., Choi P.H., Gougoutas C.A., et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223 (2002) 495-499
68. Funt S.A., Hricak H., Abu-Rustum N., Mazumdar M., Felderman H., and Chi D.S. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182 (2004) 393-398
69. Kerr V.E., and Cadman E. Pulmonary metastases in ovarian cancer. Cancer 56 (1985) 1209-1213
70. Dauplat J., Hacker N.F., Nieberg R.K., Berek J.S., Rose T.P., and Sagae S. Distant metastases in epithelial ovarian carcinoma. Cancer 60 (1987) 1561-1566
71. Sella T., Rosenbaum E., Edelmann D.Z., Agid R., Bloom A.I., and Libson E. Value of chest CT scans in routine ovarian carcinoma follow-up. AJR Am J Roentgenol 177 (2001) 857-859
72. Forstner R., Hricak H., Powel C.B., Azizi L., Frankel S.B., and Stern J.L. Ovarian cancer recurrence: value of MR imaging. Radiology 196 (1995) 715-720
73. Outwater E.K., Siegelman E.S., Wilson K.M., and Mitchell D.G. Benign and malignant gynecologic disease: clinical importance of fluid and peritoneal enhancement in the pelvis at MR imaging. Radiology 200 (1996) 483-488
74. Low R.N., Barone R.M., Lacey C., Sigeti J.S., Alzate G.D., and Sebrechts C.P. Peritoneal tumor: MR imaging with dilute oral barium and intravenous gadolinium-containing contrast agents compared with unenhanced MR imaging and CT. Radiology 204 (1997) 513-520
75. Park C.M., Kim S.H., Kim S.H., Moon M.H., Kim K.W., and Choi H.J. Recurrent ovarian malignancy: patterns and spectrum of imaging findings. Abdom Imaging 28 (2003) 404-415
76. Buist M.R., Golding R.P., Burger C.W., et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol 52 (1994) 191-198
77. Low R.N., Saleh F., Song S.Y., et al. Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination-a longitudinal study. Radiology 211 (1999) 519-528
78. Balestreri L., Bison L., Sorio R., Morra A., Campagnutta E., and Morassut S. Abdominal recurrence of ovarian cancer: value of abdominal MR in patients with positive CA125 and negative CT. Radiol Med (Torino) 104 (2002) 426-436
79. Ricke J., Sehouli J., Hach C., Hanninen E.L., Lichtenegger W., and Felix R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol 13 (2003) 943-949
80. Kim C.K., Park B.K., Choi J.Y., Kim B.G., and Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J Comput Assist Tomogr 31 (2007) 868-875
81. Havrilesky L.J., Kulasingam S.L., Matchar D.B., and Myers E.R. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 97 (2005) 183-191
82. Ak I., Stokkel M.P., and Pauwels E.K. Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 126 (2000) 560-574
83. Yen R.F., Sun S.S., Shen Y.Y., Changlai S.P., and Kao A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 21 (2001) 3691-3694
84. Torizuka T., Nobezawa S., Kanno T., et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-d-glucose. Eur J Nucl Med Mol Imaging 29 (2002) 797-803
85. Bristow R.E., Simpkins F., Pannu H.K., Fishman E.K., and Montz F.J. Positron emission tomography for detecting clinically occult surgically resectable metastatic ovarian cancer. Gynecol Oncol 85 (2002) 196-200
86. Zimny M., Siggelkow W., Schroder W., et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83 (2001) 310-315
87. Menzel C., Döbert N., Hamscho N., et al. The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer. Strahlenther Onkol 180 (2004) 497-501
88. Murakami M., Miyamoto T., Iida T., et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 16 (2006) 99-107
89. Berger K.L., Nicholson S.A., Dehdashti F., and Siegel B.A. FDG-PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 174 (2000) 1005-1008
90. Martinez-Roman S., Ramirez P.T., Oh J., Viciedo M.G., and MacApinlac H.A. Combined positron emission tomography and computed tomography for the detection of recurrent ovarian mucinous adenocarcinoma. Gynecol Oncol 96 (2005) 888-891
91. Avril N., Sassen S., Schmalfeldt B., et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 23 (2005) 7445-7453
92. Thrall M.M., DeLoia J.A., Gallion H., and Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105 (2007) 17-22
93. Townsend D.W., Carney J.P., Yap J.T., and Hall N.C. PET/CT today and tomorrow. J Nucl Med 45 Suppl 1 (2004) 4S-14S
94. Siegel B.A., and Dehdashti F. Oncologic PET/CT: current status and controversies. Eur Radiol 15 Suppl 4 (2005) D127-D132
95. Cho S.M., Ha H.K., Byun J.Y., et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR 179 (2002) 391-395
96. Bristow R.E., del Carmen M.G., Pannu H.K., et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined FDG-PET/CT. Gynecol Oncol 90 (2003) 519-528
97. Pannu H.K., Cohade C., Bristow R.E., Fishman E.K., and Wahl R.L. FDG-PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation. Abdom Imaging 29 (2004) 398-403
98. Nanni C., Rubello D., Farsad M., et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31 (2005) 792-797
99. Chung H.H., Kang W.J., Kim J.W., et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 34 (2007) 480-486
100. Hauth E.A., Antoch G., Stattaus J., et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur J Radiol 56 (2005) 263-268
101. Mangili G., Picchio M., Sironi S., et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging 34 (2007) 658-666
102. Bristow R.E., Giuntoli II R.L., Pannu H.K., et al. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 99 (2005) 294-300
103. Fanti S., Nanni C., Castellucci P., et al. Supra-clavicular lymph node metastatic spread in patients with ovarian cancer disclosed at 18F-FDG-PET/CT: an unusual finding. Cancer Imaging 6 (2006) 20-23
104. Simcock B., Neesham D., Quinn M., Drummond E., Milner A., and Hicks R.J. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 103 (2006) 271-276
105. Jänicke F., Hölscher M., Kuhn W., et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70 (1992) 2129-2136
106. Segna R.A., Dottino P.R., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11 (1993) 434-439
107. Vaccarello L., Rubin S.C., Vlamis V., et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57 (1995) 61-65
108. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., and Genazzani A.R. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79 (2000) 344-349
109. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 99 (2002) 1008-1013
110. Ayhan A., Gultekin M., Taskiran C., et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 194 (2006) 49-56
111. Chi D.S., McCaughty K., Diaz J.P., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
112. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., and Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92 (2005) 1026-1032
113. Tebes S.J., Sayer R.A., Palmer J.M., Tebes C.C., Martino M.A., and Hoffman M.S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 106 (2007) 482-487
114. Salani R., Santillan A., Zahurak M.L., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 (2007) 685-691
115. Harter P., Bois A., Hahmann M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13 (2006) 1702-1710
116. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
117. Scarabelli C., Gallo A., and Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83 (2001) 504-512
118. Zang R.Y., Li Z.T., Tang J., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 (2004) 1152-1161
119. Benedetti Panici P., De Vivo A., Bellati F., et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 14 (2007) 1136-1142
120. Benedetti Panici P., Perniola G., Angioli R., et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer 17 (2007) 1245-1251
121. Santillan A., Karam A.K., Li A.J., et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 104 (2007) 686-690